Panch.Organics (531726)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 1/1

Key Financials

Strengths

• P/E of 11.61 is modest and dividend yield of 2.95% provides some income cushion.
• Piotroski F-Score of 7/9 indicates generally sound financials and accounting quality.
• ROCE of 13.64% is above ROE of 9.38%, showing reasonable capital efficiency.
• Latest quarterly net margin of roughly 15% (₹4 Cr net profit on ₹27 Cr sales) is respectable.

Concerns

• Sales growth of 1.87% and profit growth of 0.27% are nearly stagnant; PEG of 10.85 makes the valuation expensive on a growth-adjusted basis.
• Stock is at its 52-week high of ₹241.55 after rising from ₹86.10, leaving limited margin of safety.
• Promoter holding and debt/equity are listed as N/A, creating a transparency gap.
• ROE of 9.38% is mediocre for a quality pharma investment.

AI Analysis

At ₹241.55, Panch.Organics is a small pharmaceutical business with a market cap of ₹318 Cr. I begin by asking whether it is a wonderful business at a fair price or a fair business at a wonderful price. Here, I see a fair business at best. Sales growth of just 1.87% and profit growth of 0.27% show a company that is barely moving. Latest quarter revenue of ₹27 Cr and net profit of ₹4 Cr imply a healthy net margin of about 15%, but that single quarter does not a compounder make. The P/E of 11.61 looks cheap, but the PEG of 10.85 tells the real story: earnings growth is nearly nil, so the market is paying a low multiple for even lower growth. A dividend yield of 2.95% gives some income cushion. Financially, ROCE of 13.64% is decent and above ROE of 9.38%, suggesting reasonable capital efficiency. Book value is ₹103.38; at 2.34 times book, I am not getting a bargain. The Piotroski F-Score of 7/9 is reassuring, but promoter holding and debt/equity are not disclosed. That lack of transparency bothers me. In a competitive pharmaceutical market, I cannot see a wide moat at this small scale. The stock has run from ₹86.10 to ₹241.55 in its 52-week range and now sits at the high. Chasing a stagnant earner at its peak is contrary to Graham's margin of safety. I would wait for either stronger growth or a much lower price. This is a slow grower, not a stalwart compounder.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer